ASCLF - Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
Deals and Financings
Suzhou Innovent Bio (IVBIY) [HK:01801] expanded its 2015 alliance with Eli Lilly (LLY) for Tyvyt®, Innovent's anti-PD-1 immunotherapy (see story). In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets. Lilly will pay $200 million upfront and up to $825 million in milestones, plus tiered double-digit royalties on net sales. Innovent and Lilly started co-marketing Tyvyt in China as a third-line treatment for classic Hodgkin's lymphoma in 2019.
JD Health, the healthcare arm of China's JD.com (JD), will raise more